Biomm S.A. (BVMF:BIOM3)

Market Cap	839.37M
Revenue (ttm)	139.03M
Net Income (ttm)	-67.35M
Shares Out	126.99M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177,000
Average Volume	81,405
Open	7.40
Previous Close	7.40
Day's Range	6.61 - 7.41
52-Week Range	6.30 - 10.73
Beta	0.90
RSI	21.34
Earnings Date	Nov 14, 2025

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 130
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIOM3

Financial Performance

In 2024, Biomm's revenue was 142.91 million, an increase of 20.91% compared to the previous year's 118.19 million. Losses were -77.24 million, -4.81% less than in 2023.